KM Research Hub

LITERATURE

原始候选快照

v3 复核前的候选池,完整保留,仅供查看,不会自动重新处理。 共 7004 篇。

导出 CSV
论文标识日期入排置信度入排依据KM 状态
Immunogenicity and safety of DS-5670d, an omicron XBB.1.5-targeting COVID-19 mRNA vaccine: A phase 3, randomized, active-controlled study.PLoS MedPMID 41082550PMC125174952025-Oct0.98未发现恶性肿瘤人群证据。已完成
Impact of ERCC1 on the outcomes of chemotherapy in advanced biliary tract cancer.Sci Rep疑似漏检:论文标题/摘要/图注含 OS/PFS/DFS/EFS/survival 等生存终点信号,但当前未得到 KM 提取结果。 已检查 3 张 PMC Figure,均未识别为 KM 图:Fig. 1:CONSORT/入组流程图;Fig. 2:非 KM 图;Fig. 3:非 KM 图。PMID 41028776PMC124850962025-Sep-300.98原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。无 KM 图
Mirikizumab impact on disease clearance in patients with moderately to severely active ulcerative colitis: analysis of a pre-specified LUCENT trial endpoint.J Crohns Colitis已检查 2 张 PubMed Figure,均未识别为 KM 图:Figure 1:森林图/亚组分析图;Figure 2:AI 判定为 other。PMID 40651005PMC125610012025-Sep-280.98未发现恶性肿瘤人群证据。无 KM 图
Vericiguat for patients with heart failure and reduced ejection fraction across the risk spectrum: an individual participant data analysis of the VICTORIA and VICTOR trials.LancetPubMed 未展示 Figure,且无可用 PMC 全文;如需图片,需要从出版社页面获取。PMID 40897188无 PMCID2025-Sep-270.98未发现恶性肿瘤人群证据。无 KM 图
Vericiguat in patients with chronic heart failure and reduced ejection fraction (VICTOR): a double-blind, placebo-controlled, randomised, phase 3 trial.LancetPubMed 未展示 Figure,且无可用 PMC 全文;如需图片,需要从出版社页面获取。PMID 40897189无 PMCID2025-Sep-270.98未发现恶性肿瘤人群证据。无 KM 图
Once-daily oral icotrokinra versus placebo and once-daily oral deucravacitinib in participants with moderate-to-severe plaque psoriasis (ICONIC-ADVANCE 1 & 2): two phase 3, randomised, placebo-controlled and active-comparator-controlled trials.LancetPubMed 未展示 Figure,且无可用 PMC 全文;如需图片,需要从出版社页面获取。PMID 40976249无 PMCID2025-Sep-270.98未发现恶性肿瘤人群证据。无 KM 图
Outcomes of Psoriasis Area and Severity Index (PASI) and PASI components in two phase III trials of deucravacitinib in patients with moderate to severe plaque psoriasis.Clin Exp DermatolPubMed 未展示 Figure,且无可用 PMC 全文;如需图片,需要从出版社页面获取。PMID 40411449无 PMCID2025-Sep-250.98未发现恶性肿瘤人群证据。无 KM 图
Measurable Residual Disease-Guided Therapy for Chronic Lymphocytic Leukemia.N Engl J Med疑似漏检:论文标题/摘要/图注含 OS/PFS/DFS/EFS/survival 等生存终点信号,但当前未得到 KM 提取结果。 当前未获得可用 PubMed/PMC Figure 图源,建议后续从出版商页补图源。PMID 40521799无 PMCID2025-Sep-250.95Eligible. This is an original report of a Phase III randomized trial in human chronic lymphocytic leukemia (oncology) with drug-containing interventions and primary/key secondary time-to-event efficacy endpoints (PFS, OS) with hazard ratios and Kaplan-Meier estimates provided.无 KM 图
Early Tirofiban Infusion after Intravenous Thrombolysis for Stroke.N Engl J MedPubMed 未展示 Figure,且无可用 PMC 全文;如需图片,需要从出版社页面获取。PMID 40616232无 PMCID2025-Sep-250.98未发现恶性肿瘤人群证据。无 KM 图
Ibrutinib plus rituximab vs ibrutinib monotherapy in patients with Waldenström macroglobulinemia: a pooled analysis.Blood Adv入排复审未纳入:未发现恶性肿瘤人群证据。PMID 40674744PMC124662662025-Sep-230.98未发现恶性肿瘤人群证据。无 KM 图
[Preoperative short-course radiotherapy followed by chemotherapy and PD-1 inhibitor administration for locally advanced rectal cancer: the initial results of a randomized controlled clinical trial (STELLAR II)].Zhonghua Zhong Liu Za ZhiAI 判定该论文不进入自动 KM 提取:This is an interim analysis of a seamless phase II/III trial. The reported results are from the initial 100 patients, focusing on short-term efficacy (CR rate), which is the primary endpoint for the phase II portion. The phase III component (3-year DFS) has not been reported.PMID 40967882无 PMCID2025-Sep-230.98原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。无 KM 图
Nivolumab-AVD Versus Brentuximab Vedotin-AVD in Older Patients With Advanced-Stage Classic Hodgkin Lymphoma Enrolled on S1826.J Clin OncolKM panel re-extraction failedPMID 40523203PMC123534092025-Sep-200.98原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。无 KM 图
Dual Immune Check Point Blockade in MGMT-Unmethylated Newly Diagnosed Glioblastoma: NRG Oncology BN007, a Randomized Phase II/III Clinical Trial.J Clin OncolAI 判定该论文不进入自动 KM 提取:The study is a Phase II/III trial that was stopped before Phase III analysis was performed; only Phase II results are reported.PMID 40779733PMC124402842025-Sep-200.98原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。无 KM 图
Orforglipron, an Oral Small-Molecule GLP-1 Receptor Agonist, in Early Type 2 Diabetes.N Engl J MedPubMed 未展示 Figure,且无可用 PMC 全文;如需图片,需要从出版社页面获取。PMID 40544435无 PMCID2025-Sep-180.98未发现恶性肿瘤人群证据。无 KM 图
Low-Dose Aspirin for PI3K-Altered Localized Colorectal Cancer.N Engl J Med疑似漏检:论文标题/摘要/图注含 OS/PFS/DFS/EFS/survival 等生存终点信号,但当前未得到 KM 提取结果。 当前未获得可用 PubMed/PMC Figure 图源,建议后续从出版商页补图源。PMID 40961426无 PMCID2025-Sep-180.60Aspirin is a generic/OTC drug, not a novel investigational or marketed oncology therapeutic. The explicit inclusion criterion 'drug-containing intervention' is interpreted to require a novel or marketed therapeutic agent under evaluation, not a repurposed, low-cost, non-patented compound like aspirin. Therefore, the drug_intervention criterion is not met.无 KM 图
Gut microbiome modulates the outcome in primary central nervous system lymphoma patients undergoing chemotherapy: An ancillary study from the BLOCAGE trial.Neuro Oncol疑似漏检:论文标题/摘要/图注含 OS/PFS/DFS/EFS/survival 等生存终点信号,但当前未得到 KM 提取结果。 当前未获得可用 PubMed/PMC Figure 图源,建议后续从出版商页补图源。PMID 40048707PMC124489042025-Sep-170.98原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。无 KM 图
Phenomapping-derived selection of fractional flow reserve or optical coherence tomography to personalise percutaneous coronary intervention.Open Heart入排复审未纳入:未发现恶性肿瘤人群证据。PMID 40967674PMC124587272025-Sep-170.98未发现恶性肿瘤人群证据。无 KM 图
Rasch analysis of the NEI-VFQ-25: vision-related quality of life in Leber hereditary optic neuropathy after lenadogene nolparvovec gene therapy.BMJ Open Ophthalmol已检查 2 张 PubMed Figure,均未识别为 KM 图:Figure 1:AI 判定为 other;Figure 2:AI 判定为 other。PMID 40967677PMC124587202025-Sep-170.98未发现恶性肿瘤人群证据。无 KM 图
Impact of Setmelanotide on Metabolic Syndrome Risk in Patients With Bardet-Biedl Syndrome.J Clin Endocrinol Metab已检查 3 张 PubMed Figure,均未识别为 KM 图:Figure 1:AI 判定为 other;Figure 2:AI 判定为 other;Figure 3:森林图/亚组分析图。PMID 39919037PMC124486222025-Sep-160.98未发现恶性肿瘤人群证据。无 KM 图
Doravirine/Islatravir (100/0.75 mg) Once-Daily Compared With Bictegravir/Emtricitabine/Tenofovir Alafenamide as Initial HIV-1 Treatment: 48-Week Results From a Phase 3, Randomized, Controlled, Double-Blind, Noninferiority Trial.Clin Infect Dis疑似漏检:论文标题/摘要/图注含 OS/PFS/DFS/EFS/survival 等生存终点信号,但当前未得到 KM 提取结果。 已检查 4 张 PMC Figure,均未识别为 KM 图:Graphical Abstract:AI 判定为 other;Figure 1.:AI 判定为 flow diagram;Figure 2.:森林图/亚组分析图;Figure 3.:AI 判定为 other。PMID 40079835PMC124486262025-Sep-160.98未发现恶性肿瘤人群证据。无 KM 图
Toripalimab Combination Therapy Without Concurrent Cisplatin for Nasopharyngeal Carcinoma: The DIAMOND Randomized Clinical Trial.JAMAPMID 40839372PMC123715492025-Sep-160.96主要研究目的为安全性/毒性或卫生经济学,未见合格 time-to-event 疗效终点。已完成
The effect of adjunctive cariprazine on symptoms of anhedonia in patients with major depressive disorder.J Affect DisordPubMed 未展示 Figure,且无可用 PMC 全文;如需图片,需要从出版社页面获取。PMID 40339720无 PMCID2025-Sep-150.98未发现恶性肿瘤人群证据。无 KM 图
Comparative Efficacy of Potassium-Competitive Acid Blocker-Based Triple Therapy with Tegoprazan versus Vonoprazan for Helicobacter pylori Eradication: A Randomized, Double-Blind, Active-Controlled Pilot Study.Gut Liver疑似漏检:论文标题/摘要/图注含 OS/PFS/DFS/EFS/survival 等生存终点信号,但当前未得到 KM 提取结果。 已检查 3 张 PMC Figure,均未识别为 KM 图:Fig. 1:CONSORT/入组流程图;Fig. 2:CONSORT/入组流程图;Fig. 3:非 KM 图。PMID 40462641PMC124360482025-Sep-150.98未发现恶性肿瘤人群证据。无 KM 图
Comparing the Efficacy and Safety of Fexuprazan and Lansoprazole for the Prevention of Nonsteroidal Anti-inflammatory Drug-Induced Peptic Ulcer.Gut Liver已检查 3 张 PubMed Figure,均未识别为 KM 图:Fig. 1:AI 判定为 flow diagram;Fig. 2:AI 判定为 forest plot;Fig. 3:AI 判定为 other。PMID 40567214PMC124360612025-Sep-150.98未发现恶性肿瘤人群证据。无 KM 图
Efficacy of natalizumab in secondary progressive multiple sclerosis: analysis of two phase III trials.J Neurol Neurosurg PsychiatryPubMed 未展示 Figure,且无可用 PMC 全文;如需图片,需要从出版社页面获取。PMID 40050011无 PMCID2025-Sep-120.98未发现恶性肿瘤人群证据。无 KM 图
Analysis of treatment-free survival of patients with advanced melanoma receiving nivolumab as monotherapy or in combination with relatlimab in RELATIVITY-047.J Immunother CancerPMID 40940136PMC125193872025-Sep-120.96属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。已完成
Acalabrutinib-obinutuzumab improves survival vs chemoimmunotherapy in treatment-naive CLL in the 6-year follow-up of ELEVATE-TN.BloodPMID 40198878PMC128246922025-Sep-110.98原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。已完成
Aficamten or Metoprolol Monotherapy for Obstructive Hypertrophic Cardiomyopathy.N Engl J MedPubMed 未展示 Figure,且无可用 PMC 全文;如需图片,需要从出版社页面获取。PMID 40888697无 PMCID2025-Sep-110.98未发现恶性肿瘤人群证据。无 KM 图
Mavacamten in Symptomatic Nonobstructive Hypertrophic Cardiomyopathy.N Engl J MedPubMed 未展示 Figure,且无可用 PMC 全文;如需图片,需要从出版社页面获取。PMID 40888717无 PMCID2025-Sep-110.98未发现恶性肿瘤人群证据。无 KM 图
Effect of methylcobalamin on capecitabine induced hand-foot syndrome in patients with HER2 negative early breast cancer: multicentre, double blind, randomised, placebo controlled, phase 3 trial.BMJ已检查 3 张 PubMed Figure,均未识别为 KM 图:Fig 1:CONSORT/入组流程图;Fig 2:森林图/亚组分析图;captionless-figure:AI 判定为 other。PMID 40935571PMC124239382025-Sep-110.96主要研究目的为安全性/毒性或卫生经济学,未见合格 time-to-event 疗效终点。无 KM 图
Neoadjuvant Osimertinib for Resectable EGFR-Mutated Non-Small Cell Lung Cancer.J Clin OncolPMID 40454705PMC129944802025-Sep-100.98原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。已完成
Primary Analysis of EPIK-O/ENGOT-ov61: Alpelisib Plus Olaparib Versus Chemotherapy in Platinum-Resistant or Platinum-Refractory High-Grade Serous Ovarian Cancer Without BRCA Mutation.J Clin Oncol疑似漏检:论文标题/摘要/图注含 OS/PFS/DFS/EFS/survival 等生存终点信号,但当前未得到 KM 提取结果。 当前未获得可用 PubMed/PMC Figure 图源,建议后续从出版商页补图源。PMID 40700681无 PMCID2025-Sep-100.98原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。无 KM 图
The association between pretreatment emotional distress and response to tumor-infiltrating lymphocyte therapy in advanced melanoma.Eur J Cancer入排复审未纳入:属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。PMID 40674829无 PMCID2025-Sep-090.96属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。无 KM 图
Impact of concomitant medication on recurrence, survival and tolerability of chemotherapy in early colon cancer patients - A post-hoc analysis of the PETACC 8 trial.Eur J Cancer疑似漏检:论文标题/摘要/图注含 OS/PFS/DFS/EFS/survival 等生存终点信号,但当前未得到 KM 提取结果。 当前未获得可用 PubMed/PMC Figure 图源,建议后续从出版商页补图源。PMID 40680466无 PMCID2025-Sep-090.96属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。无 KM 图
Impact of trifluridine/tipiracil plus bevacizumab on tumor shrinkage and depth of response in refractory metastatic colorectal cancer: analysis of the SUNLIGHT trial.Eur J Cancer疑似漏检:论文标题/摘要/图注含 OS/PFS/DFS/EFS/survival 等生存终点信号,但当前未得到 KM 提取结果。 当前未获得可用 PubMed/PMC Figure 图源,建议后续从出版商页补图源。PMID 40694985无 PMCID2025-Sep-090.96属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。无 KM 图
Subcutaneous versus intravenous amivantamab, both in combination with lazertinib, in refractory EGFR-mutated non-small cell lung cancer: Patient satisfaction and resource utilization results from the PALOMA-3 study.Eur J Cancer疑似漏检:论文标题/摘要/图注含 OS/PFS/DFS/EFS/survival 等生存终点信号,但当前未得到 KM 提取结果。 当前未获得可用 PubMed/PMC Figure 图源,建议后续从出版商页补图源。PMID 40730077无 PMCID2025-Sep-090.70The report is an original result from a Phase III randomized trial with a drug intervention for a human oncology condition. However, it is excluded because it does not present a primary or key secondary time-to-event efficacy endpoint (e.g., OS, PFS) as required; its focus is on patient satisfaction, resource utilization, and secondary safety/experience outcomes.无 KM 图
Improved clinical outcomes with low-dose anti-CTLA-4 (Nurulimab) plus anti-PD-1 (Prolgolimab) vs. anti-PD-1 monotherapy in advanced cutaneous melanoma: Results from the phase III OCTAVA trial.Eur J Cancer疑似漏检:论文标题/摘要/图注含 OS/PFS/DFS/EFS/survival 等生存终点信号,但当前未得到 KM 提取结果。 当前未获得可用 PubMed/PMC Figure 图源,建议后续从出版商页补图源。PMID 40795521无 PMCID2025-Sep-090.98原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。无 KM 图
Fruquintinib in less pretreated patients: Multivariate profile-matching analysis of FRESCO-2 to FRESCO.Eur J Cancer疑似漏检:论文标题/摘要/图注含 OS/PFS/DFS/EFS/survival 等生存终点信号,但当前未得到 KM 提取结果。 当前未获得可用 PubMed/PMC Figure 图源,建议后续从出版商页补图源。PMID 40795524无 PMCID2025-Sep-090.98原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。无 KM 图
Outcomes for FOLFIRI plus bevacizumab or cetuximab in patients treated with oxaliplatin-based adjuvant therapy: A combined analysis of FIRE-3 and CALGB/SWOG 80405 (Alliance).Eur J Cancer疑似漏检:论文标题/摘要/图注含 OS/PFS/DFS/EFS/survival 等生存终点信号,但当前未得到 KM 提取结果。 当前未获得可用 PubMed/PMC Figure 图源,建议后续从出版商页补图源。PMID 40803104PMC130755482025-Sep-090.98原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。无 KM 图
Efficacy and safety of upadacitinib maintenance therapy in patients with moderately to severely active Crohn's disease: 2-year results from the U-ENDURE Long-Term Extension study.J Crohns Colitis入排复审未纳入:未发现恶性肿瘤人群证据。PMID 40704669PMC124599862025-Sep-070.98未发现恶性肿瘤人群证据。无 KM 图
Effective nutritional intervention improves the health-related quality of life (HRQL) of undernourished children with cancer: results of a randomized, controlled phase 3 trial.Support Care Cancer已检查 3 张 PubMed Figure,均未识别为 KM 图:Fig. 1:AI 判定为 other;Fig. 2:AI 判定为 other;Fig. 3:AI 判定为 other。PMID 40913629PMC124140552025-Sep-060.85The trial is a definitive Phase III RCT in oncology, but it evaluates a quality-of-life outcome related to nutritional intervention rather than survival, progression, recurrence, death, or other time-to-event efficacy outcomes required for the cohort.无 KM 图
FOXC1 Expression Predicts Capecitabine Efficacy in Patients with Triple-Negative Breast Cancer from the GEICAM_CIBOMA Trial.Clin Cancer ResPMID 40569606PMC124027802025-Sep-020.98原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。已完成
Alteplase for Acute Ischemic Stroke at 4.5 to 24 Hours: The HOPE Randomized Clinical Trial.JAMA已检查 3 张 PubMed Figure,均未识别为 KM 图:Figure 1:AI 判定为 flow diagram;Figure 2:AI 判定为 other;Figure 3:森林图/亚组分析图。PMID 40773205PMC123327592025-Sep-020.98未发现恶性肿瘤人群证据。无 KM 图
Effect of PCSK9 Inhibition With Alirocumab in Patients With Probable Familial Hypercholesterolemia or Type III Hyperlipoproteinemia: Results From the ODYSSEY OUTCOMES Trial.J Am Heart Assoc已检查 2 张 PubMed Figure,均未识别为 KM 图:Figure 1:AI 判定为 other;Figure 2:AI 判定为 other。PMID 40847481PMC125534352025-Sep-020.98未发现恶性肿瘤人群证据。无 KM 图
QuANTUM-First: Clinical Validation of the LeukoStrat Companion Diagnostic for the Selection of Patients With Acute Myeloid Leukemia Harboring FMS-Like Tyrosine Kinase 3-Internal Tandem Duplications for Treatment With Quizartinib.Arch Pathol Lab MedAI 判定该论文不进入自动 KM 提取:This record reports results of a bridging/validation study for a companion diagnostic assay, not the primary Phase III randomized controlled clinical trial. The abstract describes the assay agreement and treatment efficacy in a bridging population, not the primary trial design, randomization, or results.PMID 40892059无 PMCID2025-Sep-020.98原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。无 KM 图
Covered versus uncovered endoluminal stenting in the acute management of obstructing colorectal cancer in the palliative setting: randomized clinical trial (CReST2).Br J SurgPMID 40966674PMC124488512025-Sep-020.98原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。已完成
Chemoradiotherapy With or Without Simultaneous Integrated Boost for Cervical Cancer With Full-Thickness Stromal Invasion: A Phase 3 Randomized Clinical Trial.JAMA Netw OpenPMID 40971156PMC124497252025-Sep-020.98原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。已完成
Impact of hematopoietic cell transplantation and quizartinib in newly diagnosed patients with acute myeloid leukemia and FMS-like tyrosine kinase 3-internal tandem duplications in the QuANTUM-First trial.HaematologicaPMID 40079105PMC123999592025-Sep-010.96属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。已完成
Isatuximab plus bortezomib, lenalidomide, and dexamethasone for transplant-ineligible newly diagnosed multiple myeloma patients: a frailty subgroup analysis of the IMROZ trial.Haematologica疑似漏检:论文标题/摘要/图注含 OS/PFS/DFS/EFS/survival 等生存终点信号,但当前未得到 KM 提取结果。 已检查 4 张 PMC Figure,均未识别为 KM 图:Figure 1.:森林图/亚组分析图;Figure 2.:森林图/亚组分析图;Figure 3.:生活质量量表图;Figure 4.:森林图/亚组分析图。PMID 40109195PMC123999422025-Sep-010.96属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。无 KM 图
Comprehensive Molecular Analysis in NRG Oncology/RTOG 9813: A Phase 3 Study of Radiation and Temozolomide Versus Radiation and BCNU/CCNU in Anaplastic Astrocytoma.Int J Radiat Oncol Biol Phys疑似漏检:论文标题/摘要/图注含 OS/PFS/DFS/EFS/survival 等生存终点信号,但当前未得到 KM 提取结果。 已检查 4 张 PMC Figure,均未识别为 KM 图:Figure 1.:森林图/亚组分析图;Figure 2.:非 KM 图;Figure 3.:非 KM 图;Figure 4.:非 KM 图。PMID 40164352PMC128572542025-Sep-010.98原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。无 KM 图